CORRECTION

Open Access

Correction: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Faiza Naseer[1,2*], Kousain Kousar[1], Maisa S. Abduh[3], Sadia Anjum[4] and Tahir Ahmad[1*]

*Correspondence:
faiza.naseer@ymail.com;
tahir@asab.nust.edu.pk

[1] Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan
[2] Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan
[3] Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, Jeddah 21589, Saudi Arabia
[4] Department of Biology, University of Hail, Hail, Saudi Arabia

Correction: Cancer Nanotechnology (2023) 14:65
https://doi.org/10.1186/s12645-023-00218-2

Following publication of the original article (Naseer et al. 2023), the below Acknowledgement was missing.

Acknowledgement

The original article (Naseer et al. 2023) has been corrected.

Published online: 06 July 2023

Reference

Naseer F, Kousar K, Abduh MS, Anjum S, Ahmad T (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nano 14:65. https://doi.org/10.1186/s12645-023-00218-2

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.